Concepedia

Author

Sergey Alekseev

The Maria Sklodowska-Curie National Research Institute of OncologyORCID

Also Known As

S. Alekseev, S. M. Alekseev, Sergey Alekseev

15

Publications

1.2K

Citations

6

H-Index

13

Concepts

All Affiliations

The Maria Sklodowska-Curie National Research Institute of OncologyUniversity of BolognaMemorial Sloan Kettering Cancer CenterCentre Antoine LacassagneInstitute of Oncology NN Petrov
SA

About

Sergey Alekseev is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in radiation oncology, pathology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

187

2

Pathology

2

2

187

3

Health Sciences

1

1

34

4

Cellular Therapies

1

1

34

5

Immunology

1

1

34

Sergey Alekseev

×

6

Publications

1.2K

Citations

6

H-Index

YearCitations

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus,

New England Journal of Medicine

2017

738

The microRNA-15 family inhibits the TGFβ-pathway in the heart

Anke J. Tijsen, Ingeborg van der Made, Maarten M.G. van den Hoogenhof,

Cardiovascular Research

2014

162

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors,

The Lancet Haematology

2021

153

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

David J. Straus, Monika Długosz‐Danecka, Sergey Alekseev,

Blood

2020

109

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro,

Journal of Clinical Oncology

2020

34

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

David J. Straus, Graham P. Collins, Jan Walewski,

Leukemia & lymphoma/Leukemia and lymphoma

2020

19

Page 1